D. Boral Capital Reiterates Buy Rating for Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $12.00 price target on the stock.

CARM has been the subject of a number of other reports. Evercore ISI reiterated an “in-line” rating and set a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Finally, Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $4.94.

Carisma Therapeutics Stock Down 0.6 %

CARM stock opened at $0.47 on Monday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The company’s 50 day moving average is $0.69 and its 200 day moving average is $0.93. The stock has a market cap of $19.67 million, a price-to-earnings ratio of -0.30 and a beta of 1.44. Carisma Therapeutics has a 1-year low of $0.38 and a 1-year high of $2.94.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31). The business had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. Sell-side analysts predict that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Carisma Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CARM. Barclays PLC increased its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the last quarter. Wexford Capital LP grew its position in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Carisma Therapeutics during the second quarter valued at approximately $40,000. 44.27% of the stock is owned by institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.